AB-Biotics provided earnings guidance for the full year of 2013. For the period, the company forecasts a net loss of EUR 1.8 million (USD 2.475 million), significantly below the EUR 3.9 million expectations of analysts. The company made an important effort to adjust its operating costs, which went down by 35%, with loss before interest, tax, depreciation and amortisation (LBITDA) seen at EUR 1.56 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
2022 | AB-Biotics, S.A. acquired Alifarm S.A. for EUR 3.5 million. | CI |
2019 | Kaneka Europe Holding Company N.V. completed the acquisition of 18.21% stake in AB-Biotics, S.A. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 69.57M | |
-16.96% | 11.65B | |
-30.43% | 2.33B | |
-11.81% | 2.2B | |
-23.56% | 1.6B | |
+36.79% | 1.2B | |
-3.28% | 758M | |
-12.67% | 529M | |
-36.53% | 475M | |
+13.72% | 338M |
- Stock Market
- Equities
- ABB Stock
- News AB-Biotics, S.A.
- AB-Biotics Provides Earnings Guidance for the Full Year of 2013